title: Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease.
abstract: To evaluate efficacy, safety, metabolic and clinical effects of propentofylline in Alzheimer's disease (AD), a prospective, randomized, double-blind, placebo-controlled trial was performed in 30 patients with mild to moderate AD who underwent pretreatment and posttreatment 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography under resting conditions and during stimulation with an auditory memory paradigm. Twenty-eight subjects completed the 3-month study. The drug was well tolerated. In the active treatment group, a significant increase of cerebral metabolic response to the memory task was observed (multiple measurement ANOVA P = 0.02). The placebo group showed a significantly decline in the MMSE score (P = 0.02) while there was no change in the treatment group. This suggests a protective role for propentofylline in slowing the progression of AD.
authors.affiliation: Max-Planck-Institut für Neurologische Forschung und Universitätsklinik für Neurologie, Köln, Germany. ruediger.mielke@pet.mpin-koeln.mpg.de
authors.forename: R
authors.initials: R
authors.lastname: Mielke
authors.forename: M
authors.initials: M
authors.lastname: Ghaemi
authors.forename: J
authors.initials: J
authors.lastname: Kessler
authors.forename: B
authors.initials: B
authors.lastname: Kittner
authors.forename: B
authors.initials: B
authors.lastname: Szelies
authors.forename: K
authors.initials: K
authors.lastname: Herholz
authors.forename: W D
authors.initials: WD
authors.lastname: Heiss
mesh_terms: D000161:Acoustic Stimulation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D000704:Analysis of Variance; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D011594:Psychometrics; D014055:Tomography, Emission-Computed; D014970:Xanthines / Q000627:therapeutic use*
chemical_list: D005462:Fluorine Radioisotopes; D018696:Neuroprotective Agents; D014970:Xanthines; D019788:Fluorodeoxyglucose F18; C032114:propentofylline; D005947:Glucose